Published in J Cell Biochem on January 01, 2002
The amazing osteocyte. J Bone Miner Res (2011) 5.32
Osteocytes: master orchestrators of bone. Calcif Tissue Int (2013) 2.48
Cellular and molecular mechanisms of bone remodeling. J Biol Chem (2010) 2.39
Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res (2009) 1.84
Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone (2007) 1.79
Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther (2009) 1.28
Bone metabolism in obesity and weight loss. Annu Rev Nutr (2012) 1.28
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res (2011) 1.23
Effect of low-magnitude, high-frequency vibration on osteocytes in the regulation of osteoclasts. Bone (2010) 1.22
Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS One (2012) 0.99
Seasonal changes in the lower jaw skeleton in male Atlantic salmon (Salmo salar L.): remodelling and regression of the kype after spawning. J Anat (2003) 0.94
Inhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE. Calcif Tissue Int (2010) 0.90
TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction. Endocrinology (2011) 0.90
The past, present, and future of bone morphometry: its contribution to an improved understanding of bone biology. J Bone Miner Metab (2005) 0.90
Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem (2008) 0.86
Drilling K-wires, what about the osteocytes? An experimental study in rabbits. Arch Orthop Trauma Surg (2007) 0.84
The osteocyte: key player in regulating bone turnover. RMD Open (2015) 0.83
Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone. Bone (2013) 0.82
Loading and skeletal development and maintenance. J Osteoporos (2010) 0.80
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev (2016) 0.79
Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment. Bone (2013) 0.79
Treatment with α-lipoic acid enhances the bone healing after femoral fracture model of rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.79
Microbeads-Guided Reconstruction of 3D Osteocyte Network during Microfluidic Perfusion Culture. J Mater Chem B Mater Biol Med (2015) 0.79
NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases. Adv Protein Chem Struct Biol (2016) 0.78
Ex vivo 3D osteocyte network construction with primary murine bone cells. Bone Res (2015) 0.78
Bone loss following spinal cord injury in a rat model. J Neurotrauma (2012) 0.78
Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis. J Biol Chem (2014) 0.77
Well plate-based perfusion culture device for tissue and tumor microenvironment replication. Lab Chip (2015) 0.76
Gap Junctions and Biophysical Regulation of Bone Cells. Clin Rev Bone Miner Metab (2010) 0.76
Advancing our understanding of osteocyte cell biology. Ther Adv Musculoskelet Dis (2009) 0.76
Osteocyte culture in microfluidic devices. Biomicrofluidics (2015) 0.75
Rapid phenotyping of knockout mice to identify genetic determinants of bone strength. J Endocrinol (2016) 0.75
Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab (2012) 1.49
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res (2002) 1.46
Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther (2008) 1.39
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38
Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res (2005) 1.36
Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res (2004) 1.28
Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab (2006) 1.22
Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem (2004) 1.17
Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res (2003) 1.16
Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients. J Orthop Res (2010) 1.16
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res (2004) 1.15
Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic (2003) 1.14
The critical role of IL-34 in osteoclastogenesis. PLoS One (2011) 1.14
FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer (2008) 1.13
Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech (2003) 1.13
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res (2005) 1.12
Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res (2007) 1.11
Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem (2004) 1.11
Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun (2005) 1.11
Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate (2009) 1.06
Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci (2006) 1.06
Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts. J Biol Chem (2005) 1.01
Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res (2010) 0.99
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis (2004) 0.98
Membrane-bound carbonic anhydrases in osteoclasts. Bone (2006) 0.98
Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res (2006) 0.97
Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases. Matrix Biol (2005) 0.96
Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab (2008) 0.95
Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone (2005) 0.93
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res (2005) 0.93
Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem Biophys Res Commun (2002) 0.92
Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology (2006) 0.92
Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol (2005) 0.91
Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods (2012) 0.91
Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol (2011) 0.91
Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care (2009) 0.91
RNA interference tolerates 2'-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers (2007) 0.89
Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer (2009) 0.89
Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent. Biochem Biophys Res Commun (2002) 0.88
The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res (2003) 0.88
Inhibition of the osteoclast V-ATPase by small interfering RNAs. FEBS Lett (2005) 0.88
Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol (2008) 0.88
Urinary osteocalcin as a marker of bone metabolism. Clin Chem (2005) 0.88
Potential function for the ROS-generating activity of TRACP. J Bone Miner Res (2003) 0.87
Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun (2005) 0.86
Pharmacological sequestration of intracellular cholesterol in late endosomes disrupts ruffled border formation in osteoclasts. J Bone Miner Res (2005) 0.86
Cystatin B as an intracellular modulator of bone resorption. Matrix Biol (2006) 0.86
Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1. Matrix Biol (2010) 0.86
A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform. Calcif Tissue Int (2010) 0.86
Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone (2008) 0.86
FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem (2009) 0.86
The architecture of microtubular network and Golgi orientation in osteoclasts--major differences between avian and mammalian species. Exp Cell Res (2003) 0.84
Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat (2003) 0.83
Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab (2008) 0.82
Microdamage detection and repair in bone: fracture mechanics, histology, cell biology. Technol Health Care (2009) 0.81
Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules. Biochem Biophys Res Commun (2007) 0.81
Rab13 is upregulated during osteoclast differentiation and associates with small vesicles revealing polarized distribution in resorbing cells. J Histochem Cytochem (2012) 0.81
Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat (2003) 0.81
Recombinant VSV G proteins reveal a novel raft-dependent endocytic pathway in resorbing osteoclasts. Exp Cell Res (2008) 0.80
Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase. Arch Biochem Biophys (2006) 0.79
Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium. Biochem Biophys Res Commun (2003) 0.78
Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep (2013) 0.78
Analysis by siRNA_profile program displays novel thermodynamic characteristics of highly functional siRNA molecules. Source Code Biol Med (2008) 0.78
Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun (2003) 0.77
Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. J Bone Miner Res (2012) 0.76
Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice. J Bone Miner Res (2008) 0.76
Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res (2004) 0.76
Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab (2008) 0.75
Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem (2005) 0.75